DelveInsight's Antibody-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

NEW YORK, Oct. 21, 2024 /PRNewswire/ -- Report with the AI impact on market trends- The global sexually transmitted disease ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Gilead and Merck said their once-weekly pill to treat HIV resulted in a comparable level of viral suppression compared to a ...

Biotech firm Gilead Sciences has announced plans to voluntarily withdraw the US accelerated approval for Trodelvy ...

As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

US drugmakers Gilead Sciences (Nasdaq: GILD ... Unfettered access to industry-leading news, commentary and analysis in pharma ...

Here are some regions that are attracting biotech and pharma companies.

“The RFK announcement has kind of scrambled some of the traditional thinking [about] a lot of the people that have been ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...